Others are antibodies such as Trastuzumab (Hudis, 2007; Valabrega et al., 2007), acting against human epidermal growth factor receptor 2 (HER-2) on cancer cells, or Cetuximab, that acts against the epidermal growth factor receptor (EGFR) (Cunningham et al., 2004; Bonner et al., 2006). This evidence concerns the gene ERBB2 and cancer.